This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cutler, N. R. Articles by Sramek, J. J. Search for Related Content PubMed PubMed Citation Articles by Cutler, N. R. Articles by Sramek, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1997, 1298-1300, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin

NR Cutler, J Vincent, SS Jhee, R Teng, T Wardle, G Lucas, LC Dogolo and JJ Sramek
California Clinical Trials, Beverly Hills 90211, USA.

A single-dose study was conducted to determine concentrations of trovafloxacin (CP-99,219) achieved in the cerebrospinal fluid (CSF) relative to those in the serum of healthy subjects after intravenous infusion of alatrofloxacin (CP-116,517), the alanyl-alanyl prodrug of trovafloxacin. Twelve healthy subjects were administered single doses of alatrofloxacin at a trovafloxacin equivalent of 300 mg as an intravenous infusion over 1.0 h. CSF samples were taken by lumbar puncture at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 24 h after the start of the infusion; each subject was sampled at only one time point. Serum samples were taken from each subject at the time of CSF collection. A mean concentration of 5.8 microg of trovafloxacin per ml was present in serum 1.0 h after the start of the infusion. CSF/serum ratios ranged from 0.14 to 0.33 in the postdistribution phase (5 to 24 h postinfusion), with a mean ratio of 0.25. The most common adverse events were dizziness, nausea, and rash and were mild or moderate in intensity. The potency of trovafloxacin against susceptible organisms, coupled with its rapid penetration of CSF following the intravenous administration of alatrofloxacin, suggests that it may be useful in the treatment of bacterial meningitis in humans.

This article has been cited by other articles:

• Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
• Destache, C. J., Pakiz, C. B., Larsen, C., Owens, H., Dash, A. K. (2001). Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J Antimicrob Chemother 47: 611-615 [Abstract] [Full Text]  
• Fitoussi, F., Doit, C., Geslin, P., Bingen, E. (1999). Killing Activities of Trovafloxacin Alone and in Combination with beta -Lactam Agents, Rifampin, or Vancomycin against Streptococcus pneumoniae Isolates with Various Susceptibilities to Extended-Spectrum Cephalosporins at Concentrations Clinically Achievable in Cerebrospinal Fluid. Antimicrob. Agents Chemother. 43: 2372-2375 [Abstract] [Full Text]  
• Michelet, C., Leib, S. L., Bentue-Ferrer, D., Täuber, M. G. (1999). Comparative Efficacies of Antibiotics in a Rat Model of Meningoencephalitis Due to Listeria monocytogenes. Antimicrob. Agents Chemother. 43: 1651-1656 [Abstract] [Full Text]  
• Rodoni, D., Hänni, F., Gerber, C. M., Cottagnoud, M., Neftel, K., Täuber, M. G., Cottagnoud, P. (1999). Trovafloxacin in Combination with Vancomycin against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model. Antimicrob. Agents Chemother. 43: 963-965 [Abstract] [Full Text]  
• Nicolau, D. P., Tessier, P. R., Quintiliani, R., Nightingale, C. H. (1998). Synergistic Activity of Trovafloxacin and Ceftriaxone or Vancomycin against Streptococcus pneumoniae with Various Penicillin Susceptibilities. Antimicrob. Agents Chemother. 42: 991-992 [Full Text]